Hisamitsu Pharmaceutical Co., Inc. (HTSUF)
- Previous Close
0.00 - Open
23.70 - Bid 26.81 x 40000
- Ask 30.57 x 40000
- Day's Range
23.70 - 24.56 - 52 Week Range
23.70 - 34.00 - Volume
1,351 - Avg. Volume
0 - Market Cap (intraday)
1.912B - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
19.81 - EPS (TTM)
1.24 - Earnings Date Jan 9, 2025 - Jan 13, 2025
- Forward Dividend & Yield 0.57 (2.31%)
- Ex-Dividend Date Feb 27, 2025
- 1y Target Est
--
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
www.global.hisamitsu2,759
Full Time Employees
February 29
Fiscal Year Ends
Sector
Recent News: HTSUF
View MorePerformance Overview: HTSUF
Trailing total returns as of 11/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HTSUF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HTSUF
View MoreValuation Measures
Market Cap
1.98B
Enterprise Value
1.20B
Trailing P/E
19.79
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.01
Price/Book (mrq)
1.06
Enterprise Value/Revenue
1.23
Enterprise Value/EBITDA
8.76
Financial Highlights
Profitability and Income Statement
Profit Margin
9.76%
Return on Assets (ttm)
2.48%
Return on Equity (ttm)
5.50%
Revenue (ttm)
150.19B
Net Income Avi to Common (ttm)
14.65B
Diluted EPS (ttm)
1.24
Balance Sheet and Cash Flow
Total Cash (mrq)
122.74B
Total Debt/Equity (mrq)
0.41%
Levered Free Cash Flow (ttm)
-10.55B